Continuation of nonselective beta‐blockers for patients with liver cirrhosis and hemodynamic nonresponse?
Tilman Sauerbruch – 22 July 2017
Transplant for the very sick: No limitations in donor quality?
Jennifer C. Lai – 22 July 2017
Steatotic donor livers: Where is the risk‐benefit maximized?
Matyas Hamar, Markus Selzner – 22 July 2017
Transforming growth factor‐β in liver cancer stem cells and regeneration
Shuyun Rao, Sobia Zaidi, Jaideep Banerjee, Wilma Jogunoori, Raul Sebastian, Bibhuti Mishra, Bao‐Ngoc Nguyen, Ray‐Chang Wu, Jon White, Chuxia Deng, Richard Amdur, Shulin Li, Lopa Mishra – 21 July 2017 – Cancer stem cells have established mechanisms that contribute to tumor heterogeneity as well as resistance to therapy. Over 40% of hepatocellular carcinomas (HCCs) are considered to be clonal and arise from a stem‐like/cancer stem cell.
Sequencing the gut metagenome as a noninvasive diagnosis for advanced nonalcoholic steatohepatitis
Lixin Zhu, Robert D. Baker, Ruixin Zhu, Susan S. Baker – 21 July 2017
Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1
Hui Li, Xiaoqiang Li, Shuang Liu, Lei Guo, Bo Zhang, Jubo Zhang, Qinghai Ye – 21 July 2017 – Inhibitors of programmed cell death 1 (PD‐1) administered as single agents have resulted in durable tumor regression in advanced cancer patients. However, only a minority of cancer patients respond to anti‐PD‐1 immunotherapy. Here, we show that PD‐1 expression in hepatocellular carcinoma promotes tumor growth independently of adaptive immunity. Knockdown of PD‐1 suppresses tumor growth, whereas PD‐1 overexpression enhances tumorigenesis in immunodeficient xenografted mice.
Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia
Brenda S. Hijmans, Andreas Boss, Theo H. van Dijk, Maud Soty, Henk Wolters, Elodie Mutel, Albert K. Groen, Terry G.J. Derks, Gilles Mithieux, Arend Heerschap, Dirk‐Jan Reijngoud, Fabienne Rajas, Maaike H. Oosterveer – 20 July 2017 – It is a long‐standing enigma how glycogen storage disease (GSD) type I patients retain a limited capacity for endogenous glucose production despite the loss of glucose‐6‐phosphatase activity.
Comments on “Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis”
Saeid Safiri, Salman Khazaei, Kamyar Mansori, Erfan Ayubi – 20 July 2017
Reply
Maria Kalafateli, Emmanuel A. Tsochatzis – 20 July 2017
TRAIL deletion prevents liver inflammation but not adipose tissue inflammation during murine diet‐induced obesity
Petra Hirsova, Peggy Weng, Warda Salim, Steven F. Bronk, Thomas S. Griffith, Samar H. Ibrahim, Gregory J. Gores – 20 July 2017 – Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and its cognate receptor(s) are up‐regulated in human and murine nonalcoholic steatohepatitis (NASH); however, the consequence of this enhanced expression on NASH pathogenesis remains unclear. TRAIL may either accentuate liver injury by promoting hepatic steatosis and inflammation or it may mitigate the disease process by improving systemic insulin resistance and averting hepatic fibrosis.